MARAVAI LIFESCIENCES HOLDINGS, INC.
MRVINasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M |
| Operating income | −$215.3M | −$235.6M | −$31.6M | $574.2M | $554.6M | $119.9M |
| Net income | −$130.8M | −$144.8M | −$119.0M | $220.2M | $182.0M | $89.0M |
| Total assets | $770.6M | $1.01B | $1.49B | $2.28B | $1.92B | $1.27B |
| Total liabilities | $397.9M | $431.0M | $697.6M | $1.38B | $1.37B | $1.12B |
| Equity | $212.4M | $325.3M | $416.8M | $545.2M | $315.5M | $88.5M |
| EPS (diluted) | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 |
| Shares out. | 144.4M | 137.9M | 131.9M | 255.3M | 257.8M | 28.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −115.9%
- Net margin
- −70.4%
- Return on equity
- −61.6%
- Return on assets
- −17.0%
- Return on capital (ROCE)
- −29.7%
- Liabilities / assets
- 51.6%
- Debt / equity
- 1.87×
- Book value / share
- $1.47
- Revenue growth (YoY)
- −28.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.87distress
- Accruals / assets
- −9.5%clean
- Beneish M-Score
- -2.69normal
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 4, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- 12 West Capital Management LpPassive (13G)May 15, 2026
- Feldman StuartPassive (13G)May 14, 2026
- Millennium Management LlcPassive (13G)May 12, 2026
- Vanguard Group IncPassive (13G)Oct 31, 2025
- Blackrock, Inc.Passive (13G)Oct 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Marker Luke JosephDirector | May 26, 2026 | Grant | 46,293 | $0.00 |
| Gray SusannahDirector | May 26, 2026 | Grant | 46,293 | $0.00 |
| Mihas Constantine SDirector | May 26, 2026 | Grant | 46,293 | $0.00 |
| Eckert R AndrewDirector | May 26, 2026 | Grant | 46,293 | $0.00 |
| Lucier Gregory TDirector | May 26, 2026 | Grant | 46,293 | $4.38 |
| Cunningham Sean LaurenceDirector | May 26, 2026 | Grant | 46,293 | $0.00 |
| Deford John ADirector | May 26, 2026 | Grant | 46,293 | $0.00 |
| Dolan ChristineOfficer — See Remarks | May 15, 2026 | Grant | 5,006 | $1.79 |
| Oreshack KurtOfficer — General Counsel | May 15, 2026 | Grant | 776 | $2.84 |
| Dolan ChristineOfficer — See Remarks | Mar 16, 2026 | Tax withholding | 28,661 | $3.08 |
| Oreshack KurtOfficer — General Counsel | Mar 16, 2026 | Tax withholding | 39,976 | $3.08 |
| Dolan ChristineOfficer — See Remarks | Jan 15, 2026 | Tax withholding | 28,934 | $3.69 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 8.5M | 2.7 | -4.1% |
| Apr 30, 2026 | 8.9M | 5.0 | -3.9% |
| Apr 15, 2026 | 9.2M | 4.8 | -2.8% |
| Mar 31, 2026 | 9.5M | 4.7 | -2.2% |
| Mar 13, 2026 | 9.7M | 6.6 | -8.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 29, 2026
- Results of operationsMay 7, 2026
- Results of operationsFeb 25, 2026
- Results of operationsNov 6, 2025
- Director / officer changeOct 27, 2025
- Results of operations · Costs from exit or disposal · Director / officer changeAug 11, 2025
- Changed auditorJul 18, 2025
- Director / officer change · Regulation FD disclosureJun 25, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 29, 2026
- 4/AFORM 4/AMay 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 28, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 14, 2026
- SCHEDULE 13GMay 12, 2026
- 10-QMay 8, 2026